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Background: Cannabis use and childhood maltreatment are independent risk factors for the development of
psychotic symptoms. These factors have been found to interact in some but not all studies. One of the reasons
may be that childhoodmaltreatment and cannabis primarily induce psychotic symptoms in genetically suscepti-
ble individuals. In this context, an extensively studied psychosis vulnerability gene is catechol-methyl-transferase
(COMT). Therefore, we aimed to examine whether the COMT Val158Met polymorphism (rs4680) moderates the
interaction between childhoodmaltreatment and cannabis use on psychotic symptoms in the general population.
Method: The discovery sample consisted of 918 individuals from a cross-sectional study. For replication we used
an independent sample of 339 individuals from the general population.
Results: A signiﬁcant three-way interaction was found between childhood maltreatment, cannabis use, and the
COMT genotype (rs4680) in the discovery sample (P = 0.006). Val-homozygous individuals displayed increased
psychotic experiences after exposure to both cannabis use and childhood maltreatment compared to Met-
heterozygous and Met-homozygous individuals. Supportive evidence was found in the replication sample
with similar effect and direction even though the results did not reach statistical signiﬁcance (P = 0.25).
Conclusions: These ﬁndings suggest that a functional polymorphism in the COMT gene may moderate the inter-
action between childhoodmaltreatment and cannabis use on psychotic experiences in the general population. In
conclusion, the COMT Val158Met polymorphism may constitute a genetic risk factor for psychotic symptoms in
the context of combined exposure to childhood maltreatment and cannabis use.© 2013 Elsevier B.V. All rights reserved., Brain Center Rudolf Magnus,
rglaan 100, 3584 CX Utrecht,
kers).
rights reserved.1. Introduction
A growing body of literature indicates that several environmental
risk factors are associated with the occurrence of (sub)clinical psy-
chotic symptoms (Cougnard et al., 2007; van Os et al., 2009).
Among these risk factors, childhood trauma has been consistently
found to increase the risk for psychotic symptoms, both in psychotic
disorders (Read et al., 2005; Bendall et al., 2008) and in the general
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2006; Alemany et al., 2011). In addition, cannabis use is associated
with psychosis proneness (Arseneault et al., 2004; Moore et al.,
2007; Kuepper et al., 2011b; Large et al., 2011), particularly after
early, frequent, and enduring use in adolescence (Henquet et al.,
2005; McGrath et al., 2010; Schubart et al., 2010). In light of the
established effects of childhood maltreatment and cannabis on
psychosis risk, their combination has been suggested to synergistical-
ly increase the risk for psychotic symptoms (Compton et al., 2004;
Houston et al., 2008; Harley et al., 2010; Konings et al., 2012). However,
a relation between childhood trauma, cannabis consumption, and
psychosis was not always replicated and contradicting results have
been published (Houston et al., 2011; Kuepper et al., 2011a). One of
the reasons for these conﬂicting ﬁndings may be that childhood mal-
treatment and cannabis primarily induce psychotic symptoms in genet-
ically susceptible individuals. In this context, an extensively studied
psychosis vulnerability gene is catechol-methyl-transferase (COMT)
which encodes the prime catecholamine degrading enzyme COMT. A
non-synonymous single nucleotide polymorphism (SNP) in the COMT
gene (rs4680) results in a valine-to-methionine mutation at position
158 (Val158Met). The Val variant possesses increased enzymatic activity
compared to the Met variant and directly inﬂuences dopamine metab-
olism with functional impact on the central dopamine system
(Mannisto and Kaakkola, 1999). However, the direct effect of this SNP
on psychosis and schizophrenia is unconvincing (Fan et al., 2005;
Munafo et al., 2005; Okochi et al., 2009). In the context of cannabis
use, previous studies investigating the COMT Val158Met genotype as a
moderator of the association between cannabis and psychosis found
both supportive (Caspi et al., 2005; Henquet et al., 2006; Henquet et
al., 2009; Estrada et al., 2011) as well as incongruous results (Costas et
al., 2011; van Winkel, 2011; Zammit et al., 2011). Considering the
independent effects of cannabis and childhood trauma and their possi-
ble interactional effects on (sub)clinical psychotic experiences, we
hypothesized that the COMT Val158Met polymorphism moderates the
interaction between childhood adversity and cannabis use. More
speciﬁcally, we hypothesized that Val homozygous individuals are
at increased risk for the joint effects of childhood maltreatment and
cannabis use on psychotic experiences compared to the other two ge-
notypes.We therefore examined these risk factors and their interaction
in a population-based discovery sample and an independent replication
sample.
2. Materials and methods
2.1. Samples
2.1.1. Discovery sample
Participants in the discovery sample were recruited using a project
website launched in 2006 targeted at Dutch young adults and adoles-
cents from 18 to 25 years (www.cannabisquest.nl) (Schubart et al.,
2010). Strategies to generate trafﬁc on the project website included
collaboration with over a hundred colleges, universities, and youth
centres, as well as the use of online commercial advertisement
products (i.e. banners and text links) (Schubart et al., 2010). The
chance to win an Apple iPod™ or a NintendoWii™was used as an in-
centive. Double entries were prevented by exclusion of subjects with
an identical e-mail address, surname, and date of birth. Anonymous
submission of data was not possible. The online assessment included
veriﬁcation questions to protect against random answers, and partic-
ipants failing to correctly complete the veriﬁcation questions were
subsequently excluded. From the online data (N = 17,698), 1259
participants were included for subsequent genetic assessment in
two waves. First, in order to increase power for gene × environment
interactions (Boks et al., 2007), we prioritized a sample of 719 partic-
ipants who belonged to the top or bottom quintile of total scores of
psychotic experiences as measured by the Community Assessmentof Psychic Experiences (CAPE) score (see below) that were either
cannabis naïve (i.e. a lifetime cannabis exposure frequency less than
6 times) or were heavy cannabis users (i.e. current expenditure for
personal cannabis use exceeded 3€ weekly). Second, an unselected
sample of 540 individuals was included. As ascertained with the val-
idated Dutch version of either the Structured Clinical Interview
(SCID) (First et al., 1997) or the MINI International Neuropsychiatric
Interview (Sheehan et al., 1998), healthy controls had no history of
any psychotic disorder. For 84 participants no interview data were
available and for these cases, the presence of a psychotic disorder
was excluded by the absence of antipsychotic drug use or a history
of psychiatric treatment. A signiﬁcant three-way interaction between
childhood maltreatment, cannabis use, and the COMT Val158Met
polymorphism remained present after exclusion of the 84 individ-
uals without a diagnostic interview (P = 0.0064). The possible con-
comitant use of recreational drugs was assessed with the substance
abuse module of the Composite International Diagnostic Interview
(Compton, 1993). Of the 1259 participants that completed compre-
hensive assessments and provided blood samples for genetic testing,
complete data were available for 918 subjects due to a later implemen-
tation of the Childhood Trauma Questionnaire (CTQ) assessment in the
study, with 525 individuals from the ﬁrst tier and 393 individuals
from the second tier. All participants provided a urine sample to
screen for the presence of recreational drugs in order to verify recent
self-reported cannabis use. The study was approved by the Ethical
Review Board of the UniversityMedical Center Utrecht and all partic-
ipants gave written informed consent.
2.1.2. Replication sample
Healthy participants were selected from the Genetic Risk and
Outcome of Psychosis (GROUP) study, a multisite longitudinal cohort
study in The Netherlands and Belgium investigating schizophrenia
patients, siblings, and healthy controls (Korver et al., 2012). In selected
representative geographical areas in The Netherlands, controls were
selected through a system of random mailings in the catchment
areas of the cases. The full GROUP sample consists of patients with
non-affective psychotic disorder, siblings of these patients, parents
of the patients and their siblings, and unrelated controls. General in-
clusion criteria were: (1) age range of 16–50 years and (2) good com-
mand of the Dutch language. Exclusion criteria for healthy controls
were a history of psychotic disorder or a ﬁrst-degree or second-degree
family member with a history of psychotic disorder as established
by the Family Interview for Genetic Studies. Out of 419 healthy con-
trols, we succeeded in obtaining complete data for 339 individuals,
of which 285 healthy controls were assessed at two time points
and 54 healthy controls only once. Thus, in total, 624 measurements
were available for the analysis (285 × 2 + (339 − 285)). Of the
339 healthy controls, 41 individuals were related healthy siblings,
i.e. more than one individual from a healthy family. The study protocol
was approved centrally by the Ethical Review Board of the University
Medical Center Utrecht and subsequently by local review boards of
each participating institute. All participants gave written informed
consent.
2.2. Measures
2.2.1. Cannabis consumption
In the discovery sample, cannabis use was deﬁned as current use
more than an equivalent of 3€ euro per week (roughly equivalent to
weekly cannabis use) during the last month or longer. The monetary
amount spent on cannabis has been reported as a valid proxy of expo-
sure to Δ9-tetrahydrocannabinol (THC) (Niesink et al., 2009). In the
replication sample, cannabis use was derived from the Composite In-
ternational Diagnostic Interview (CIDI) with the pattern of cannabis
use during the last year as main outcome (hereafter referred to as
‘cannabis use’) (van Winkel, 2011). Outcomes of cannabis use during
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daily (3). Moreover, a dichotomous cannabis measure (cannabis use
versus no cannabis use) was analyzed in the replication sample to
allow for a direct comparison with the discovery sample with regard
to cannabis use.
2.2.2. Childhood maltreatment
In both the discovery and replication samples, childhood maltreat-
ment was assessed using the 25-item version of the Childhood Trauma
Questionnaire (CTQ) (Bernstein and Fink, 1998). The CTQ assesses
ﬁve types of self-report childhood trauma: emotional abuse, physical
abuse, sexual abuse, emotional neglect and physical neglect. The valid-
ity of the CTQ, including a Dutch translation, has been demonstrated in
clinical and community samples (Bernstein and Fink, 1998; Thombs et
al., 2009). One translated item (“I believe I was molested”) was exclud-
ed in the discovery sample as this translationwas found to be an invalid
indicator of childhood sexual abuse in a previous validation study
(Thombs et al., 2009). Childhood maltreatment was used as the contin-
uous sum score divided by the number of completed items. One item of
the CTQ in the discovery sample was only available for a subset of the
discovery sample (“My family was a source of strength and support”).
Additional analyses in which this item was excluded altogether did
not affect the results. In the replication sample, all CTQ items were
available.
2.2.3. Psychotic experiences
The Community Assessment of Psychic Experiences (CAPE) was
used to assess psychotic experiences in both samples. This validated
42-item self-report questionnairemeasures the prevalence of psychotic
experiences on a frequency scale ranging from ‘never’ (1), ‘sometimes’
(2), ‘often’ (3), to ‘nearly always’ (4) and displays discriminative validity
in assessing psychotic experiences in the general population (Konings
et al., 2006). Scores were transposed to zero for absent symptoms and
divided by the number of completed items to deal with missingness
as previously described (Konings et al., 2006). Thus, total CAPE scores
may vary between 0 and 3. From the total CAPE score, dimensions
of positive, negative, and depressive symptoms may be extracted
which are signiﬁcantly correlated (Stefanis et al., 2002). Therefore, we
also analyzed the effects of childhood maltreatment, cannabis use,
and the COMT Val158Met genotype on these three dimensions of psy-
chosis for the discovery sample using multiple analysis of covariance
(MANCOVA).
2.3. Genotyping procedures
2.3.1. Discovery sample
All participantswere of Dutch ancestry. Genotype datawere generat-
ed on three different array platforms: the IlluminaHumanOmniExpress
(N = 576), the IlluminaHuman610-QuadBeadchip (N = 768), and the
IlluminaHumanHap550 array (N = 34). For each SNP platform, quality
control procedures were initially performed separately using PLINK
V1.07 (Purcell et al., 2007). Subjects were excluded based on N5% miss-
ing genotypes and gender errors. We used linkage disequilibrium (LD)
based SNP pruning to select the most informative SNPs (R2 b 0.2),
only for the subsequent quality control step. This resulted in ~67k
SNPs for the sets to assess heterozygosity (F b 3SD), homozygosity
(F N 3SD) and relatedness by pairwise IBD values (pihat N 0.15).
Datasets were merged with Hapmap Phase 3 individuals to check eth-
nicity. After these QC procedures on subjects (excluding in total 101 in-
dividuals), quality control on SNPs was performed as follows. All SNPs
were ﬁltered onmissingness (inclusion with b2%) and HardyWeinberg
(inclusion P N 1e−6) before merging the three datasets. Four duplicates
and three related sample-pairs were detected in the merged datasets
(according to criteria described above) and one outlier after clustering
the merged dataset. From these data, the COMT Val158Met genotype
(rs4680) was extracted.2.3.2. Replication sample
The COMT Val158Met genotype was determined by Sequenom
(Hamburg, Germany) using the SequenomMassARRAY iPLEX platform
at the facilities of themanufacturer, using the SNP array described in the
previous work (van Winkel et al., 2011).
2.4. Statistical analysis
To examine the interaction between COMT, cannabis use, and child-
hood maltreatment on psychotic experiences, the total CAPE score
was regressed on cannabis use, childhood maltreatment, COMT
rs4680 genotype, their interaction, and covariates using the fol-
lowing model: CAPE = β0 + (β1 ∗ covariate) + (β2 ∗ rs4680) +
(β3 ∗ cannabis use) + (β4 ∗ childhood maltreatment) + (β5 ∗ rs4680 ∗
cannabis use) + (β6 ∗ rs4680 ∗ childhood maltreatment) + (β7 ∗
rs4680 ∗ cannabis use ∗ childhood maltreatment). To enhance the
interpretation of the three-way interaction, we also tested the main
effects of childhoodmaltreatment, cannabis use, and theCOMTVal158Met
genotype on psychotic symptoms as well as the two-way interactions
between these variables. Moreover, to facilitate the interpretation of
the interaction, we also calculated the zero-order associations between
childhood trauma, cannabis use, and the COMT Val158Met genotype in
the discovery and replication sample. In the discovery sample, cannabis
use was modeled as a dichotomous indicator and included covariates
were age and gender. In the replication sample, a mixed model was
used to account for family relatedness and repeated measures with age,
sex, and ethnic background as covariates. Random effects were unique
subject number and family number. Analyses were performed with the
nlme package in R (www.r-project.org) (Pinheiro et al., 2012). A priori
planned stratiﬁed analyses were carried out for cannabis use and the
three genotypes of the COMT Val158Met polymorphism.
Genotypes were coded 0, 1, or 2 and modeled as a linear effect
(additive genetic model) to account for different genotype distribu-
tions because it avoids small subgroup stratiﬁcation (Cordell and
Clayton, 2005). Cannabis use in the replication sample was analyzed
as a linear effect as applied in previous papers (van Winkel et al.,
2011). Continuous sum scores of the CAPE and the CTQ were used
in both the discovery and replication samples. Difference in group
characteristics was tested using an independent t-test or chi-square
test where appropriate.
2.4.1. Effect analysis
To facilitate the interpretation of the three-way interaction be-
tween childhood maltreatment, cannabis use, and COMT, we ﬁrst
conducted an effect analysis of this interaction using the effects pack-
age in R (Fox, 2003). This allows the study of individual parameters of
general and mixed models while adjusting for covariates and other
ﬁxed effects. This method is particularly useful to investigate how
complex interactions behave for several values. We examined the
three-way interaction for ﬁve equally spaced levels of the full range
of CTQ scores.
3. Results
3.1. Sample characteristics
Table 1 reports the distribution of demographic characteristics,
cannabis use, levels of maltreatment, psychotic experiences (CAPE),
and the COMT Val158Met genotype in the discovery and replication
sample. The reported levels of psychotic experiences, cannabis use,
and childhood maltreatment are consistent with previous research
and representative of young populations (Bernstein and Fink, 1998;
Stefanis et al., 2002). Moreover, the characteristics in the discovery
sample generalize to the full sample which includes all non-
genotyped individuals (Schubart et al., 2010). Genotyping of rs4680
was successful in all subjects and no departure fromHWEwas detected
Table 1
Characteristics of the discovery sample and the replication sample. P values refer to the
comparison between the discovery and replication sample.
Parameter Discovery sample
CannabisQuest
(N = 918)
Replication
sample GROUP
(N = 339)a
P value
Female sex, % 53 57 b0.001
Age, mean (range), year 20 (18–40) 32 (16–56) b0.001
Dutch ethnicity, % 100% 90% b0.001
CTQd score, mean (range) 1.40 (1.00–4.26) 1.33 (1.0–2.95) b0.001
Cannabis use in the past year b0.001
N3€/week, % 33
Daily, % 2
Weekly, % 4
Less, % 8
None, % 86
COMT Val158Met genotype
(rs4680)
0.77
G/G (val/val), % 20 24
A/G (met/val), % 50 49
A/A (met/met), % 30 27
HWEb P-value 0.88 0.59 N/A
CAPEc, mean (range) 0.61 (0.02–2.48) 0.38 (0.0–1.29) P b 0.001
a With a total of 624 (repeated) measurements.
b Hardy–Weinberg Equilibrium.
c Community Assessment of Psychic-like Experiences.
d Childhood Trauma Questionnaire.
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notype minor allele frequency was comparable to previously reported
frequencies in a population of European descent (Caspi et al., 2005;
Zammit et al., 2011). The discovery and replication sample differed
signiﬁcantly with respect to age (t = 26.8, P b 0.001), gender (χ2 =
13.98, P b 0.001), the number of cannabis users (χ2 = 151.32,
P b 0.001), and frequency of psychotic experiences (t = 15.87,
P b 0.001) (Table 1). In both samples, the COMT Val158Met genotype
was not associated with childhood maltreatment (discovery sample:
P = 0.94; replication sample: P = 0.15) or cannabis use (discovery
sample: P = 0.88; replication sample: P = 0.20). In the discovery
sample, cannabis use was associated with increased levels of childhood
maltreatment (P b 0.001), but this effect was absent in the replication
sample (P = 0.60). Levels of cannabis use and childhood maltreatment
in Val/Val-carriers in the discovery sample and the replication sample
are reported in Table 2.
3.2. Effect analyses
First, to understand how childhood trauma interacts with cannabis
use and the COMT genotype, we completed an effect analysis using
ﬁve equal parts of the full range of the Childhood TraumaQuestionnaire
score in the discovery and replication sample. Fig. 1 illustrates that in
Val/Val individuals who use cannabis, increased levels of childhood
maltreatment are associated with increased self-report levels of the
CAPE score. In the replication sample, a similar pattern is apparent,Table 2
Cannabis use and levels of childhood maltreatment in Val/Val-carriers in the discovery
sample and replication sample.
Discovery sample
Val/Val-carriers (N = 185) N CTQ score (mean)
Cannabis use Yes 58 1.34
No 127 1.26
Replication sample
Val/Val-carriers (N = 84) Observations CTQ score (mean)
Cannabis use Yes 17 1.27
No 133 1.30
CTQ: Childhood Trauma Questionnaire.with increasing levels of childhood maltreatment resulting in a marked
increase in psychotic experiences in Val/Val individuals who use canna-
bis (Fig. 1).
3.3. Main effects and two-way interactions in the discovery and replica-
tion sample
In the discovery sample, childhood maltreatment (β = 0.38,
P b 0.001), cannabis use (β = 0.14, P b 0.001) but not the COMT
Val158Met genotype (β = −0.015, P = 0.35) were signiﬁcantly asso-
ciated with psychotic symptoms. In the replication sample, similar
results were obtained, with signiﬁcant main effects of childhood mal-
treatment (β = 0.29, P b 0.001), cannabis use (β = 0.036, P =
0.033) but not the COMT Val158Met genotype (β = −0.014, P = 0.41).
With regard to two-way interactions, the discovery and replication
sample showed comparable results. No signiﬁcant interactions were
present between childhood maltreatment and cannabis use (discovery:
β = −0.059, P = 0.34; replication: β = −0.024, P = 0.66), as well as
cannabis use and the COMT Val158Met genotype (discovery: β = 0.011,
P = 0.75; replication: β = 0.019, P = 0.44). In contrast, childhood
maltreatment and the COMT Val158Met genotype signiﬁcantly interacted
in the discovery sample (β = 0.14, P = 0.0039) and the replication
sample (β = −0.12, P = 0.022). After testing themain and two-way in-
teractions, analyses were carried out for the three-way interaction be-
tween childhood maltreatment, cannabis use and the COMT Val158Met
genotype in the discovery sample (Section 3.4) and the replication
sample (Section 3.5).
3.4. Childhood maltreatment, cannabis use, COMT Val158Met genotype,
and psychotic experiences in the discovery sample
Table 3 shows the results of the linear regression model in the
discovery sample. Signiﬁcant effects on psychotic experiences were
present for maltreatment (β = 0.27, P = 0.023), cannabis use
(β = 0.72, P = 0.008), and their interaction (β = −0.47, P =
0.019). Moreover, there was a signiﬁcant three-way interaction be-
tween cannabis use, childhood maltreatment and the COMT genotype
(β = 0.29, P = 0.006). For individuals carrying the Val/Val COMT ge-
notype, cannabis use in combination with increased levels of childhood
maltreatment resulted in increased levels of subclinical psychotic expe-
riences (Fig. 2A). Sex, age, and the COMT Val158Met genotype were not
signiﬁcantly associated with the presence of psychotic experiences.
Subsequently, we analyzed the positive, negative, and depressive
dimensions of the CAPE questionnaire. The interaction between child-
hood maltreatment, cannabis use, and the COMT Val158Met genotype
was signiﬁcant for negative (P = 0.004) and depressive (P = 0.007)
dimensions of the CAPE questionnaire in the discovery sample but
not for the positive dimension (P = 0.10).
3.5. Childhood maltreatment, cannabis use, COMT Val158Met genotype,
and psychotic experiences in the replication sample
In the replication sample, childhood maltreatment (β = 0.44,
P b 0.001) and the COMT Val158Met genotype (β = 0.18, P = 0.019)
were signiﬁcantly associated with psychotic experiences (Table 3).
Moreover, sex and agewere also signiﬁcantly associatedwith psychotic
experiences. There was no signiﬁcant effect of cannabis use in
predicting psychotic experiences (β = 0.16, P = 0.14). The interaction
between cannabis use and childhood maltreatment was not signiﬁcant
(β = −0.11, P = 0.18). In addition, no signiﬁcant three-way interac-
tion between cannabis use, childhood maltreatment and the COMT
genotype was found (β = 0.10, P = 0.25), even though a similar di-
rection of the effect of cannabis use and childhood maltreatment in
Val/Val individuals was apparent (Fig. 2B). To allow for comparison
between the discovery and replication sample, dichotomized cannabis
use (no use vs. any cannabis use) was subsequently analyzed in the
Fig. 1. Effect analyses investigating the interaction between childhood maltreatment, cannabis use, and the COMT Val158Met genotype for ﬁve equal parts of the full range of the
childhood maltreatment questionnaire (CTQ) score. Both in the discovery sample (top panel) and the replication sample (bottom panel), Val-homozygous individuals display
increased levels of psychotic symptoms after cannabis use and childhood maltreatment.
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(β = 0.43, P b 0.001) and an increased albeit non-signiﬁcant result
of the interaction between cannabis use, childhood maltreatment, and
the COMT genotype (β = 0.29, P = 0.11).Table 3
The effects of cannabis use, childhood maltreatment, and COMT Val158Met genotype
(rs4680) and their interaction on psychotic experiences in the discovery sample and
replication sample.
Sample Beta SE t-Value P value
Discovery sample: CannabisQuest
Intercept 0.337 0.183 1.84 0.066
Sex −0.037 0.023 −1.63 0.104
Age −0.003 0.004 −0.78 0.435
Childhood maltreatment 0.273 0.120 2.28 0.023⁎
rs4680 −0.062 0.081 −0.77 0.443
Cannabis 0.721 0.273 2.64 0.008⁎⁎
Maltreatment × rs4680 0.035 0.062 0.57 0.569
Maltreatment × cannabis −0.474 0.201 −2.36 0.019⁎
Cannabis × rs4680 −0.390 0.141 −2.77 0.006⁎⁎
Maltreatment × cannabis × rs4680 0.290 0.104 2.78 0.006⁎⁎
Replication sample: GROUP
Intercept −0.123 0.092 −1.33 0.18
Sex 0.048 0.023 2.11 0.03⁎
Age −0.002 0.001 −2.83 0.005⁎⁎
Ethnicity −0.037 0.036 −1.03 0.30
Childhood maltreatment 0.438 0.067 6.59 b0.001⁎⁎⁎
Cannabis 0.162 0.109 1.49 0.14
rs4680 0.177 0.075 −1.33 0.019⁎
Maltreatment × rs4680 −0.145 0.056 −2.59 0.010⁎
Maltreatment × cannabis −0.113 0.083 −1.35 0.18
Cannabis × rs4680 −0.117 0.115 −1.02 0.31
Maltreatment × cannabis × rs4680 0.102 0.089 1.14 0.25
⁎ P b 0.05.
⁎⁎ P b 0.01.
⁎⁎⁎ P b 0.001.3.6. Stratiﬁed analysis of cannabis use and the COMT Val158Met genotype
in both samples
In the discovery sample, stratiﬁed analysis of cannabis users
showed that the effect of childhood maltreatment on psychotic
symptoms was most pronounced in Val/Val-carriers (childhood
maltreatment × COMT Val158Met genotype interaction, β = 0.56,
P b 0.001). In contrast, no signiﬁcant interaction was present be-
tween the COMT Val158Met genotype and childhood maltreatment
in individuals who did not use cannabis in the discovery sample
(β = 0.066, P = 0.52). In contrast, Val/Val-carriers who did not use
cannabis reported lower levels of psychotic symptoms compared to the
other genotypes in the replication sample (childhood maltreatment ×
COMT Val/Met genotype interaction, β = −0.12, P = 0.034). In indi-
viduals from the replication samplewhoused cannabis, no signiﬁcant in-
teractionwas present (β = −0.069, P = 0.61). These stratiﬁed analyses
suggest that the effect of childhood maltreatment on psychotic symp-
toms in Val/Val-carriers depends on cannabis use. Additionally, planned
stratiﬁed analysis of the COMT Val/Met genotypes in the discovery
sample resulted in consistent trends for the interaction between
cannabis use and childhood maltreatment but did not reach statistical
signiﬁcance (Met/Met: β = −0.39, P = 0.08; Val/Met: β = 0.23, P =
0.098; Val/Val: β = 0.56, P = 0.08). In the replication sample, the
interaction between childhood maltreatment and cannabis use did
not reach statistical signiﬁcance in any of the genotypes (Met/Met:
β = −0.08, P = 0.40; Val/Met: β = −0.15, P = 0.064; Val/Val: β =
0.20, P = 0.30).
4. Discussion
We examined the effects of childhood maltreatment, cannabis use,
the COMT Val158Met polymorphism (rs4680) on psychotic experi-
ences in the general population. In the discovery sample, we found
Fig. 2. Interaction between childhood maltreatment, cannabis use, and the COMT Val158Met COMT genotype on psychotic experiences (Community Assessment of Psychic Experiences,
CAPE) in the discovery sample (A) and the replication sample (B).
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cannabis use, and the common COMT(Val/Met) genotype. Consistent
with our hypothesis, Val/Val carriers who used cannabis and who
had been exposed to higher levels of childhood maltreatment report-
ed increased levels of psychotic experiences (Fig 2A). We attempted
to replicate this gene–environment–environment interaction in the
healthy individuals of the GROUP sample, a multisite longitudinal
cohort study in The Netherlands and Belgium investigating schizo-
phrenia patients, siblings, and healthy controls (Korver et al., 2012).
In this sample, the three-way interaction between childhood mal-
treatment, cannabis use, and COMT had a similar directionality
(Fig. 2B) but did not reach statistical signiﬁcance. Both in the discov-
ery and the replication sample, Val/Val individuals who used cannabis
were the most susceptible to the effects of childhood maltreatment
(Fig. 1). Considering previous evidence that the functionality of the
dopamine system is affected by cannabis use (Bossong et al., 2009;
Kuepper et al., 2010) and childhood maltreatment (Lee and Coccaro,
2010; Rodrigues et al., 2011), it may be hypothesized that childhood
maltreatment and cannabis use increase psychosis risk in Val/Val
carriers as a result of altered dopamine levels (Tunbridge et al., 2006).
The more heat-stable Val-variant of the COMT enzyme (encoded by
the G allele) possesses a higher intrinsic activity compared to the
Met-variant (Mannisto and Kaakkola, 1999). As a result, the functional
COMT(Val/Met) polymorphism directly inﬂuences central dopamine
levels and is regarded as a plausible biological risk factor for psychosisin light of the dopamine hypothesis of psychosis (Akil et al., 2003).
Our ﬁnding that Val/Val carriers are associated with the highest risk
for psychotic symptoms after exposure to childhood maltreatment
and cannabis is somewhat surprising as Val-allele carriers possess an
increased activity of the COMT enzyme and are expected to have rela-
tively decreased prefrontal dopamine levels. Met/Met-carriers may be
more vulnerable to stress compared toVal-carriers, but only if no canna-
bis is consumed (Alemany et al., in press). Moreover, in patients with
a non-affective psychotic disorder, the COMT Met/Met genotype was
associated with increased negative affect and momentary psychosis in
reaction to stress compared to the Val/Met and Val/Val genotypes
(Collip et al., 2011). However, this was not the case for healthy controls.
Therefore, the role of the COMT genotype may depend on the a priori
genetic risk for psychotic symptoms. Another important consideration
is that, although COMT is expressed throughout the brain, it is of partic-
ular importance in the prefrontal cortex. In the striatum, removal of
dopamine from the synaptic cleft is mediated by the highly expressed
dopamine transporter (DAT) rather than COMT. COMT knockout mice
display major changes in dopamine levels in the prefrontal cortex
(Gogos et al., 1998), and the COMT genotype inﬂuences D1 receptor
occupation in the cortex but not in the striatum of healthy individuals
(Slifstein et al., 2008). Together, these data suggest that the COMT
Val158Met genotype is differentially involved in cortical vs. subcortical
regions. In this light, it is interesting that increased midbrain dopamine
synthesis has been found in Val-carriers which may be associated
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mesolimbic system (Meyer-Lindenberg et al., 2005). Moreover, differ-
ential COMT effects between cortical and limbic regions may be related
to differences in phasic and tonic dopaminergic transmission (Bilder
et al., 2004). Therefore, the relation between enzymatic activity of
COMT and dopaminergic activity in the brain is complex and cannot be
directly translated. Moreover, molecular changes due to the interaction
between COMT, childhood adversity, and cannabis use were not studied
in the present study and other neurotransmitter systems other than
dopamine may be involved (Behan et al., 2012). Moreover, the COMT
Val158Met polymorphism exerts pleiotropic effects on behavior and
has been implicated in other psychiatric disorders such as mood dis-
orders (Hosak, 2007). Our results conﬁrm and extend the ﬁndings
that childhood trauma is strongly associated with psychotic symp-
toms independently of cannabis and the COMT genotype (Read et al.,
2005; Bendall et al., 2008; van Os et al., 2010). In support, a signiﬁcant
main effect of childhood maltreatment remained present in both sam-
ples after exclusion of the factors cannabis use and COMT Val158Met
genotype.
We found a signiﬁcant interaction between childhood maltreat-
ment, cannabis use, and COMT in the discovery sample but not in
the replication sample. Nonetheless, the direction and effect size of
the interaction are very similar to the discovery sample. There may
be several other reasons why the initial interaction was not unequiv-
ocally conﬁrmed. First, the replication sample may have had insufﬁ-
cient statistical power to detect a three-way interaction due to a
relative smaller sample size (n = 339 vs. n = 918 in the discovery
sample). Another important factor that may have adversely inﬂuenced
the power in the replication sample is the fact that only 14% of the
individuals in the replication sample used cannabis compared to 33%
in the discovery sample. This is relevant because the power to detect
gene–environment interactions rapidly decreases with declining expo-
sure rates (Boks et al., 2007; Caspi et al., 2010). Moreover, individuals
in the replication sample reported fewer psychotic experiences. Thus,
the replication sample may have experienced too few psychotic symp-
toms to detect an interaction between cannabis use, childhoodmaltreat-
ment, and COMT. Moreover, the overall increased age of the replication
sample is of importance as adolescent but not adult-onset cannabis
use is associated with an increased risk for both clinical and subclinical
psychotic symptoms (Arseneault et al., 2002; Fergusson et al., 2003;
Schubart et al., 2010). Therefore, its interaction with genetic and other
environmental factors may be more prominent during adolescence.
In the discovery sample, no main sex effect was present. In contrast,
females reported overall increased psychotic symptoms compared to
males in the replication sample.
The interpretation of this study is constrained by several limita-
tions. First, our results do not provide information about the causality
of the interaction between childhood maltreatment, cannabis, and
COMT on psychotic experiences due to the cross-sectional nature of
the data. Second, the variable indexing cannabis use was not consis-
tent across the discovery and replication sample. In the discovery
sample, a question assessing current cannabis expenditure was
used, whereas the Composite International Diagnostic Interview
(CIDI) was used in the replication sample. Third, childhood maltreat-
ment was retrospectively assessed and may be subject to recall bias
depending on personal characteristics including the level of current
psychotic experiences. Nonetheless, CTQ scores are stable over time
and have good convergent and divergent validity (Bernstein et al.,
1994; Bernstein and Fink, 1998). Moreover, an important limitation of
this study is the sample size of both cohorts. The estimation of this
gene × environment × environment interaction therefore depends on
relatively low numbers of Val/Val carriers in the different conditions,
and further independent replication in large cohorts is required.
Nevertheless, a very recent study showed an similar interaction be-
tween exposure to childhood abuse and cannabis use on psychotic
experiences in Val-carriers (Alemany et al., in press).In conclusion, we provide suggestive evidence that the functional
COMT Val158Met polymorphism moderates the interaction between
childhood maltreatment and cannabis use on psychotic experiences
in the general population. The contributions of cannabis and child-
hood adversity on psychosis risk may be of particular signiﬁcance in
Val carriers of the COMT Val158Met genotype. The present study re-
ports a complex and hypothesis-driven gene–environment interac-
tion between two well-documented environmental psychosis risk
factors and genetic variation in the COMT gene. Our results may
explain the heterogeneous ﬁndings in the existing literature on the
psychosis-inducing effects of cannabis use and childhood maltreat-
ment. Moreover, our data demonstrate the large inﬂuence of sample
selection, environmental factor assessment, and the use of cutoff values.
Nevertheless, our comprehensive effect analyses facilitate the interpre-
tation of this complex gene–environment interaction. Overall, the pres-
ent study provides further insight into the complex interplay between
two extensively documented environmental factors and genetic back-
ground in shaping the risk for psychotic symptoms.
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